Restricted proportion of patients responding to ICB therapy aspires to an urgency, exploring precise biomarkers for screening out potential NSCLC sufferers with definite clinical efficacy, rather than mere reliance on PD‐L1 expression on tumour cells. The gene discussed is CD274; the disease is neoplasm.